

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroScientific Corporation

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

VOLUNTARY ANNOUNCEMENT

Artemis Dream® SELF-EXPANDING INTRACRANIAL RAPAMYCIN ELUTING STENT SYSTEM ENTERS THE INNOVATIVE GREEN PATH OF NMPA

This announcement is made by MicroPort NeuroScientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that Artemis Dream® Self-Expanding Intracranial Rapamycin Eluting Stent System (“**Artemis Dream®**”), developed by MicroPort NeuroTech (Shanghai) Co., Ltd., a subsidiary of the Group, has passed the special review application for innovative medical devices of National Medical Products Administration (the “**NMPA**”) and entered the special review procedure (the “**Green Path**”). To date, the Group has had seven products included in the NMPA’s special review program for innovative medical devices. The inclusion of this product marks further official recognition of the Group’s technological strategy in the field of intracranial arterial stenosis treatment.

As an innovative product developed to tackle the clinical challenges of intracranial arterial stenosis, Artemis Dream® is the first domestically-developed targeted drug-eluting self-expanding intracranial arterial stent whose core design advantages are as follows:

- **Balance radial support and long-term outcomes:** It adopts a self-expanding stent structure to precisely tune mechanical support performance and metal coverage, lowering the risk of vascular injury and restenosis from a structural perspective.

- **Realize targeted drug delivery:** Equipped with the “single-sided grooved” targeted drug delivery technology, the stent delivers superior coating adhesion durability and achieves directional drug release exclusively toward the vessel wall. It inhibits intimal hyperplasia, accelerates endothelialization, and helps shorten the postoperative dual antiplatelet therapy (DAPT) duration.

The inclusion of Artemis Dream® in the “Green Path” for innovative review will effectively shorten the product registration review cycle, accelerate the product’s market launch to benefit patients, and further enhance the Group’s comprehensive product portfolio for the treatment of ischemic cerebrovascular diseases.

There can be no assurance that Artemis Dream® will eventually be successfully commercialized. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort NeuroScientific Corporation
Dr. Zhang Jie
Chairman and Non-executive Director

Hong Kong, July 30, 2026

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Zhang Jie, Mr. Liu Xudong and Ms. Wu Xia as the non-executive directors; Dr. Zhang Haixiao, Mr. Fan Xin, Mr. Li Zhiyong and Mr. Liu Thomas A. as the independent non-executive directors.